BioSpace News Archive

Immunovant, Inc. announced that it has achieved alignment with the United States Food and Drug Administration Division of Ophthalmology on plans to initiate two placebo-controlled Phase 3 clinical trials to evaluate batoclimab in TED.

Kraig Biocraft Laboratories, Inc., the biotechnology company focused on the development and commercialization of spider silk, sends senior members of its US management and research team to Vietnam to support multiple aspects of operations focused on production expansion and development of end markets.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for BCX9250 for the prevention of heterotopic ossification (HO) in patients with fibrodysplasia ossificans progressiva (FOP).

FibroGen, Inc. (NASDAQ: FGEN) today announced completion of patient enrollment for LELANTOS-2, a Phase 3 clinical study of pamrevlumab in patients with ambulatory Duchenne muscular dystrophy (DMD).

Bausch + Lomb Announces First-Quarter 2022 Results and Provides 2022 Guidance.

Ms. Gambale’s experience in data technology and finance supports Avellino’s bioinformatics precision medicine mission.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that data from Enanta’s internal development program portfolio for hepatitis B virus (HBV) and its out-licensing program portfolio for non-alcoholic steatohepatitis (NASH) have been accepted for poster presentations at the European Association.

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Derek Maetzold, president and chief executive officer, and Frank Stokes, chief financial officer, are scheduled to present a company overview at the JMP Securities Life Sciences Conference on Thursday, June 16, 2022, at 10:30 a.m. Eastern time.

Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced new clinical data on its Omicron-containing bivalent COVID booster candidate, mRNA-1273.214, containing mRNA-1273 (Spikevax) and a vaccine candidate targeting the Omicron variant of concern.

Resverlogix Corp. (“Resverlogix”) (TSX:RVX) today announced the publication of an article entitled “ Breaking boundaries: Pan BETi disrupt 3D chromatin structure, BD2-selective BETi are strictly epigenetic transcriptional regulators ” in the journal Biomedicine & Pharmacotherapy.